middle.news
How Syntara’s SNT-9465 Could Revolutionize Scar Treatment After Phase 1a Success
9:13am on Wednesday 26th of November, 2025 AEDT
•
Healthcare
Read Story
How Syntara’s SNT-9465 Could Revolutionize Scar Treatment After Phase 1a Success
9:13am on Wednesday 26th of November, 2025 AEDT
Key Points
Phase 1a trial confirms dose-dependent target inhibition and good safety profile
Phase 1b randomized, double-blinded, placebo-controlled trial to start ahead of schedule
Parallel keloid scar study with first-generation drug reaches 50% recruitment
Results expected in 2026 to support FDA Investigational New Drug application
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Syntara (ASX:SNT)
OPEN ARTICLE